CD27/TNFRSF7 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-15790
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Summary for CD27/TNFRSF7 Antibody
Immunogen
Recombinant protein encompassing a sequence within the center region of human CD27/TNFRSF7. The exact sequence is proprietary.
Localization
Membrane
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Theoretical MW
29 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for CD27/TNFRSF7 Antibody
![Western Blot: CD27/TNFRSF7 Antibody [NBP2-15790]](https://resources.bio-techne.com/images/products/CD27-Antibody-Western-Blot-NBP2-15790-img0001.jpg "Western Blot: CD27/TNFRSF7 Antibody [NBP2-15790]")
Western Blot: CD27/TNFRSF7 Antibody [NBP2-15790]
Western Blot: CD27 Antibody [NBP2-15790] - Sample (30 ug of whole cell lysate) A: K562 10% SDS PAGE gel, diluted at 1:10000.![Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody [NBP2-15790]](https://resources.bio-techne.com/images/products/CD27-Antibody-Immunohistochemistry-Paraffin-NBP2-15790-img0002.jpg "Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody [NBP2-15790]")
Immunohistochemistry-Paraffin: CD27/TNFRSF7 Antibody [NBP2-15790]
Immunohistochemistry-Paraffin: CD27 Antibody [NBP2-15790] - Immunohistochemical analysis of paraffin-embedded Breast ca, using antibody at 1:250 dilution.Applications for CD27/TNFRSF7 Antibody
Application
Recommended Usage
Immunohistochemistry
1:100-1:1000
Immunohistochemistry-Paraffin
1:100-1:1000
Western Blot
1:5000-1:20000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
0.1M Tris (pH 7), 0.1M Glycine, 10% Glycerol
Preservative
0.01% Thimerosal
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Background: CD27/TNFRSF7
Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).
References
1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629
2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001
3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025
4. Uniprot (P26842)
5. Uniprot (P41272)
6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32
7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y
Alternate Names
CD27, TNFRSF7
Gene Symbol
CD27
Additional CD27/TNFRSF7 Products
Product Documents for CD27/TNFRSF7 Antibody
Product Specific Notices for CD27/TNFRSF7 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information go to www.P65Warnings.ca.gov.